CE / CME
In this certified on-demand webcast, experts review the latest evidence and evolving treatment strategies in renal cell carcinoma (RCC), including frontline therapy selection, updates on adjuvant pembrolizumab and HIF-2 inhibitors, emerging biomarker research, and novel approaches for refractory disease.
Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Nurse Practitioners/Nurses: 1.50 Nursing contact hours
Released: June 22, 2026
Expiration: December 21, 2026
Share
Provided by Clinical Care Options, LLC dba Decera Clinical Education
This educational activity is supported by medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck Sharp & Dohme LLC.
AVEO Pharmaceuticals, Inc.
Bristol Myers Squibb
Eisai Inc.
Exelixis, Inc.
Merck Sharp & Dohme, LLC
This activity is for oncologists, advanced practitioners, nurse practitioners, clinical nurse specialists, physician associates, pharmacists, and other healthcare professionals caring for patients with renal cell carcinoma.
This activity aims to improve learners’ knowledge, confidence, and clinical competence in applying the latest evidence from pivotal and emerging trials of immunotherapy and targeted agents to optimize treatment sequencing, biomarker-guided selection, and TRAE management in RCC.
Upon completion of this activity, participants should be able to:
Stratify RCC patients’ benefit likelihood from IO- or targeted regimens based on validated clinical, molecular, and tumor microenvironment biomarkers as well as traditional risk assessment
Plan patient-centric first- and subsequent-line therapy for advanced/metastatic RCC using up-to-date guidelines, prior therapy history, evolving biomarker insights, and practical administration considerations
Manage adverse events across all approved and emerging systemic RCC regimens, considering regimen-specific toxicity, patient comorbidities, and optimal supportive care strategies
Evaluate current and emerging data from key clinical trials and real-world evidence for new targeted, immunotherapy, and cellular therapy strategies in both clear cell and non-clear cell RCC, and advocate for clinical trial participation where appropriate
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary AuthorBradley A. McGregor, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Daiichi Sankyo, Eisai, Exelixis, Gilead, Merck, Pfizer; researcher: Arcus, Bayer.
Brian I. Rini, MD, FASCO: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol Myers Squibb, Eisai, Exelixis, Formedics, Johnson & Johnson, Merck, Pfizer, Xencor; researcher: Adela, Arcus, AstraZeneca, Aveo, Bristol Myers Squibb, Daiichi Sankyo, Deciphera, Exelixis, Genentech, Gilead, HiberCell, Incyte, Janssen, Merck, Pfizer, Point Biopharma, Regeneron, Surface Oncology, Tempus.
Karine Tawagi, MD: consultant/advisor/speaker: AstraZeneca, Cardinal Health, DAVA Oncology, Exelixis, Johnson & Johnson, Pfizer, Stemline.
The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below:
Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Stemline.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 22, 2026, through December 21, 2026:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.
Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-358-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 21, 2026. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification ![]()
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.